الصفحة 1
الصفحة 1
Hormonal control of cell cycle
This volume reflects the proceedings of an International Workshop held in Paris in December 2006. The aim of the meeting was to undertake a high level of scholarly exchange between experts in cell biology, oncology and endocrinology interested in cell cycle control. The topics covered ranged from fundamental studies of DNA replication,chromosomal and nuclear function through growth factor control of endocrine tumor initiation and progression.
Estrogen Effects in Psychiatric Disorders
A number of studies, mostly focusing on estrogen replacement therapy in women, have reported beneficial actions of these hormones on various neurobiological and neuropathological parameters in health and disease. Recent research has focused on gender differences and there is increasing evidence that estrogens exert protective effects in schizophrenia. Hormonal fluctuations or lack of estrogen may increase the risk of depression among vulnerable women. Treatment of depression with estrogen may stabilize and restore disrupted homeostasis – as during post-partum, premenstrual, or perimenopausal conditions – and act as a psychomodulator to offset vulnerability to dysphoric mood when estrogen levels are significantly decreased, as in the case of postmenopausal women. Studies on the effect of estrogens on Alzheimer’s Disease are still rather controversial, they do, however, facilitate the hypothesis that estrogens may have a modifying effect on the onset and course of AD, at least in subgroups of patients.
Lippincott illustrated reviews : Pharmacology
Presents up-to-date drug information in an accessible format ideal for a fast, effective refresher. Part of the popular Lippincott® Illustrated Reviews series, this concise resource features clear, effective writing and hundreds of illustrations that break down complex information for rapid review. Sequential images present mechanisms of action and focus on showing rather than telling students how drugs work, and review questions with answers deliver powerful, practical exam preparation. Updated drug information reflects the most current, clinically relevant pharmacology material. Approachable outline format distills complex information for easier review. High-quality illustrations reinforce understanding in vibrant detail. Enhanced review questions with answers test students' understanding and identify areas for further study.
Aromatase Inhibitors
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
Aromatase Inhibitors
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
